(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
What's the Fate of 5G Innovation? - 2Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- 3Why haven’t humans been back to the moon in over 50 years?
- 4Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- 5Most loved Well known Accessory Styles For 2024
- See the famous winged horse Pegasus fly in the autumn night sky
- Concern for couple jailed in Tehran as British embassy closes
- National health ranking puts Georgia near bottom of list. Here's why
- Flourishing in a Remote Workplace: Individual Techniques
- China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- Zelensky names spy chief to head presidential office after corruption row
- What is colostrum? And should you be taking it?
- The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
- Trying to improve your health and wellness in 2026? Keep it simple
